Articles & White Papers
By
Danelle Johnston, MSN, RN, HON-ONN, OCN,
Elaine Sein, BSN, RN,
Tricia Strusowski, RN, MS
AONN+ is proud to announce the release of its white paper, Academy of Oncology Nurse & Patient Navigators Announces Standardized Navigation Metrics. The white paper addresses the history of navigation, the motivation for creating the standardized metrics, and how it is going to be applied.
Patient navigation addresses barriers and facilitates timely access to quality standard care by providing individualized assistance to patients, survivors and families.
In a Cancer.net podcast, AONN+'s Program Director and Co-Founder Lillie Shockney, RN, BS, MAS discusses her presentation “The Value of Patient Navigators as Members of the Multidisciplinary Oncology Care Team” she made at the 2016 ASCO annual meeting. Come hear what she has to say on this significant topic.
The Navigation Metrics Team met recently to discuss the development of evidenced-based metrics within navigation related to the various components of care with the goal of rolling out these metrics and making them available so that every program can utilize them.
Medical oncologist Richard J. LoCicero, MD, believes navigators fill in the patient care blanks offering their value as coordinators, shoulders of support, and negotiators.
In the second installment of her series, AONN+ Program Director Lillie D. Shockney, RN, BS, MAS, talks about transforming patients' survivorship plans from unused medical documents into life plans that they will actively use to refer to for setting behavioral and lifestyle goals.
In the first of a 2-part series, AONN+ Program Director Lillie D. Shockney, RN, BS, MAS, addresses the importance of analyzing survivorship programs and some of the inherent challenges to do so, including a lack of clinical research and data implementation.
The scope of navigation has evolved from the Freeman model of community outreach and prevention to spanning the entire continuum of care for oncology patients. Navigators help individuals overcome barriers to care and navigate through the screening/diagnostic, treatment, survivorship, and end-of-life care continuum.
By
Kimberly Foster, MBA, BSN, RN,
Marian E. Gilmore, RN, OCN,
Pamela Goetz, BA, OPN-CG,
Barbara R. McHale, RN, BS, OCN, CBCN, ONN-CG
The case study for this discussion highlights the complexities of care coordination when patients arrive unprepared physically or mentally for the recommended medical treatments as determined by guidelines. It also shows how navigators can assemble needed care team players to efficiently guide the patient through prehabilitation and preparation for medical treatment.
By
Cheryl Bellomo, MSN, RN, HON-ONN-CG, OCN,
Deborah Christensen, RN, BSN, HNB-BC,
Tricia Strusowski, RN, MS
Along with the diagnosis of breast cancer comes many decisions regarding treatment options. Oncotype DX, a genomic/gene expression assay, provides quantitative assessment of chemotherapy benefit and risk of distant recurrence in early-stage estrogen receptor–positive (ER+), HER2/neu-negative breast cancer to assist in developing individualized treatment plans.